SKIN CARE 45 4
n Placebo n Active 4%
0 -4 -8 ** -12 D29 * D84
Figure 5: Application of an emulsion with 4% active significantly reduces skin blueness. The b* value measurement revealed a reduction in skin blueness of 3% after 29 days and 7.2% after 84 days. The effect after 84 days was significant over baseline and placebo. The statistical values in blue relate to the comparison of active with the placebo, whereas the black values relate to the comparison with the initial condition. Wilcoxon signed-rank test.
better on day 29 and day 84 than at the beginning of the study (improvement of 1.3 % and 5.3 % respectively; Fig 2). Additionally, the treatment after 84 days showed significantly better results even as compared to the placebo treatment, which did not produce a beneficial effect. The maximum height of the roughness profile (Rz) measurement showed an improvement of 1.3% after 29 days and 4.9% after 84 days respectively (data not shown), which is in agreement to the previously mentioned data.
Dark circles
The skin colour change was addressed by conventional chroma meter measurement. It revealed that application of 4% active had a
significant lightening effect on the eye area, increasing over time (Fig 3). The results revealed a significant enhancement over baseline and placebo. Additionally, skin redness was significantly
reduced during treatment with 4% active. The results showed a reduction of 8.7% after 29 days and 7.3% after 84 days (Fig 4). In addition to this, skin blueness was reduced strikingly during treatment with 4% active. The results showed a reduction of 3% after 29 days and 7.2% after 84 days (Fig 5). In summary, the lightening effect combined with the reduction of the skin redness and blueness reveal an obvious improvement in the eye area appearance, which can be seen from Figure 6.
Mean + SEM n=20; * = p<0.05 ** = p<0.01
Photographic documentation To underline the results obtained, macro photographs were taken. Figure 6 shows a representative image of subject number 21 at the beginning of the study and after 84 days of treatment with 4% active. The overall eye appearance was improved. Particularly noteworthy is the reduction of the visibility of capillary veins, which stand out through the delicate skin in the periorbital region (lower black arrows). Additionally, the dark skin regions are visibly lighter (upper black arrows).
Discussion and conclusion Today’s insanely fast-paced world combined with unhealthy lifestyle choices leave their visible traces, in particular, around our eyes. Dark circles and puffy eyes can make even the most dynamic people look dull and tired. Sleep problems, allergies, exhaustion or inherited features are just some of the factors responsible for dark circles and swollen eyes. In general, in the advanced ageing process, the tissue and muscles surrounding the eyes weaken, and protruding fat tissue contributes to the swollen appearance. Sooner or later, time or better said long days and restless nights take their toll. Concealers may camouflage the darkness under your eyes but unfortunately, they cannot addresss the problem of a swollen eye area. For this, it is necessary to analyse and treat the problem at its roots. Rahn has developed Slimexir to tackle the problem of fat excess, fluid retention and sagging skin. Application of Slimexir may significantly reduce discolouration and puffiness in the eye area. The overall eye appearance is visibly
The dermosoft®
multifunctional additives with
antimicrobial properties
Two product lines, two ways
to product safety. The Verstatil®
safe, reliable and economic
preservation systems range:
range:
November 2018
PERSONAL CARE EUROPE
Relative to initial condition (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
